Hoffmann-La Roche posts results of Phase 3 IMpower030 atezolizumab trial in resectable NSCLC
Results for the IMpower030 study were first posted on ClinicalTrials.gov on October 9, 2026. The Phase 3 trial enrolled 453 participants and completed primary data collection on October 1, 2025.
Primary source
ClinicalTrials.gov results record, October 9, 2026
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
Machine-summarized from the source above; not independently reported. How we use automation